Hospital-wide modification of fluoroquinolone policy and meticillin-resistant Staphylococcus aureus rates: a 10-year interrupted time-series analysis

被引:43
作者
Parienti, J. -J. [1 ,2 ]
Cattoir, V. [3 ]
Thibon, P. [4 ]
Lebouvier, G. [5 ]
Verdon, R. [2 ]
Daubin, C. [6 ]
du Cheyron, D. [6 ]
Leclercq, R. [2 ]
Charbonneau, P. [6 ]
机构
[1] CHU Caen, Dept Biostat & Clin Res, F-14000 Caen, France
[2] CHU Caen, Dept Infect Dis, F-14000 Caen, France
[3] CHU Caen, Dept Microbiol, F-14000 Caen, France
[4] CHU Caen, Dept Infect Control, F-14000 Caen, France
[5] CHU Caen, Dept Pharm, F-14000 Caen, France
[6] CHU Caen, Dept Crit Care Med, F-14000 Caen, France
关键词
Antibiotic stewardship; Fluoroquinolones; Meticillin-resistant Staphylococcus aureus; Time series; INFECTION-CONTROL; ANTIBIOTIC USE; RISK-FACTORS; CONSUMPTION; BACTEREMIA; PROGRAM;
D O I
10.1016/j.jhin.2011.03.008
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
In our tertiary university hospital, fluoroquinolones were prohibited during 2001 leading to a 90% reduction in their use. Our objective was to examine the trends in meticillin-resistant Staphylococcus aureus (MRSA) following the reintroduction of fluoroquinolones. We conducted a 10-year time-series analysis of monthly MRSA according to: (i) period of fluoroquinolone restriction (January 2001 to January 2002); (ii) period of fluoroquinolone increase up to pre-restriction levels (January 2002 to December 2004); and (iii) an observational period including the implementation of a hand hygiene campaign with alcohol-based hand rub (January 2005 to June 2009). We used segmented linear autoregression analysis to assess trends between adjacent periods. Fluoroquinolone use increased from 5.2 defined daily doses (DDD) per 1000 patient-days in 2001 to 56.6 DDD per 1000 patient-days in 2005 reaching pre-restriction fluoroquinolone levels (P < 0.001) and remained stable during 2005-2010 (P = 0.65). The monthly proportion of MRSA decreased during the period of FQ restriction (-0.49 per month, P < 0.05). The reintroduction of fluoroquinolones was associated with a significant increase in MRSA (+0.68 per month, P < 0.02) compared to the previous period. During period 3, we observed a significant change in MRSA (-5.9, P < 0.002) compared to the previous period (-0.32 per month, P < 0.001). During the latter period, hand hygiene was promoted and alcohol-based hand-rub consumption increased from 3411 L in 2005 to 14 599 L in 2009. This study reinforces the rationale for a hospital-wide fluoroquinolone formulary policy to control MRSA and suggests that it has an additive effect with a hand hygiene promotion. (C) 2011 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:118 / 122
页数:5
相关论文
共 19 条
[1]   Modelling the impact of antibiotic use and infection control practices on the incidence of hospital-acquired methicillin-resistant Staphylococcus aureus:: a time-series analysis [J].
Aldeyab, Mamoon A. ;
Monnet, Dominique L. ;
Maria Lopez-Lozano, Jose ;
Hughes, Carmel M. ;
Scott, Michael G. ;
Kearney, Mary P. ;
Magee, Fidelma A. ;
McElnay, James C. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (03) :593-600
[2]   Reemergence of gentamicin-susceptible strains of methicillin-resistant Staphylococcus aureus: Roles of an infection control program and changes in aminoglycoside use [J].
AubryDamon, H ;
Legrand, P ;
BrunBuisson, C ;
Astier, A ;
Soussy, CJ ;
Leclercq, R .
CLINICAL INFECTIOUS DISEASES, 1997, 25 (03) :647-653
[3]   Using interrupted time series analysis to assess associations of fluoroquinolone formulary changes with susceptibility of gram-negative pathogens and isolation rates of methicillin-resistant Staphylococcus aureus [J].
Bosso, John A. ;
Mauldin, Patrick D. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (06) :2106-2112
[4]   Fluoroquinolone use and methicillin-resistant Staphylococcus aureus isolation rates in hospitalized patients:: A quasi experimental study [J].
Charbonneau, P ;
Parienti, JJ ;
Thibon, P ;
Ramakers, M ;
Daubin, C ;
du Cheyron, D ;
Lebouvier, G ;
Le Coutour, X ;
Leclercq, R .
CLINICAL INFECTIOUS DISEASES, 2006, 42 (06) :778-784
[5]   A province-level risk factor analysis of fluoroquinolone consumption patterns in Canada (2000-06) [J].
Glass, Shiona K. ;
Pearl, David L. ;
McEwen, Scott A. ;
Finley, Rita .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (09) :2019-2027
[6]   Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus [J].
Harbarth, S ;
Liassine, N ;
Dharan, S ;
Herrault, P ;
Auckenthaler, R ;
Pittet, D .
CLINICAL INFECTIOUS DISEASES, 2000, 31 (06) :1380-1385
[8]   Fluproquinolone utilization, in the emergency departments of academic medical centers - Prevalence of, and risk factors for, inappropriate use [J].
Lautenbach, E ;
Larosa, LA ;
Kasbekar, N ;
Peng, HP ;
Maniglia, RJ ;
Fishman, NO .
ARCHIVES OF INTERNAL MEDICINE, 2003, 163 (05) :601-605
[9]   Modification in prescribing practices for third-generation cephalosporins and ciprofloxacin is associated with a reduction in meticillin-resistant Staphylococcus aureus bacteraemia rate [J].
Liebowitz, L. D. ;
Blunt, M. C. .
JOURNAL OF HOSPITAL INFECTION, 2008, 69 (04) :328-336
[10]   Fluoroquinolone prescribing in the United States: 1995 to 2002 [J].
Linder, JA ;
Huang, ES ;
Steinman, MA ;
Gonzales, R ;
Stafford, RS .
AMERICAN JOURNAL OF MEDICINE, 2005, 118 (03) :259-268